- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Pfizer acquired Biohaven's migraine business, requiring FDA approval for the resulting drug launch.
FDA accepted Pfizer's New Drug Application (NDA) for vepdegestrant, supporting the company's growth trajectory.
3 reports, 3 independent
Updated Aug 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted Pfizer's New Drug Application (NDA) for vepdegestrant, supporting the company's growth trajectory.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approval of VEPPANU triggered payments from Pfizer to Yale University.1 source
NDA acceptance for vepdegestrant from FDA on Aug 10, 2025.1 source
Keep exploring
The entities involved
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- Annovis Bio discussed p-tau217 use with the FDA and plans to submit an NDA for review.
- The FDA recommended advancement for a new drug application submitted by a company.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
Coverage
Newest first; wire copies grouped- fool.com
- Simply Wall St.FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded Pfizer recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for
- GlobeNewswireSelective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche The Global Selective Estrog